Evogene Ltd. (EVGN)
Evogene has a market cap or net worth of $32.52 million. The enterprise value is $7.43 million.
The last earnings date was Wednesday, November 15, 2023, before market open.
|Earnings Date||Nov 15, 2023|
Evogene has 50.55 million shares outstanding.
|Owned by Insiders (%)||2.04%|
|Owned by Institutions (%)||2.71%|
|EV / Earnings||n/a|
|EV / Sales||1.30|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
The company has a current ratio of 6.26, with a Debt / Equity ratio of 0.65.
|Debt / Equity||0.65|
|Debt / EBITDA||n/a|
|Debt / FCF||n/a|
Return on equity (ROE) is -97.90% and return on invested capital (ROIC) is -74.21%.
|Return on Equity (ROE)||-97.90%|
|Return on Assets (ROA)||-37.40%|
|Return on Capital (ROIC)||-74.21%|
|Revenue Per Employee||$41,766|
|Profits Per Employee||-$148,000|
In the past 12 months, Evogene has paid $16,000 in taxes.
|Effective Tax Rate||n/a|
Stock Price Statistics
The stock price has increased by +6.03% in the last 52 weeks. The beta is 1.03, so Evogene's price volatility has been similar to the market average.
|52-Week Price Change||+6.03%|
|50-Day Moving Average||0.57|
|200-Day Moving Average||0.72|
|Relative Strength Index (RSI)||60.70|
|Average Volume (30 Days)||115,114|
Short Selling Information
|Short Previous Month||180,362|
|Short % of Shares Out||0.44%|
|Short % of Float||n/a|
|Short Ratio (days to cover)||2.18|
In the last 12 months, Evogene had revenue of $5.72 million and -$20.28 million in losses. Loss per share was -$0.48.
|Loss Per Share||-$0.48|
The company has $37.23 million in cash and $12.03 million in debt, giving a net cash position of $25.20 million or $0.50 per share.
|Cash & Cash Equivalents||37.23M|
|Net Cash Per Share||$0.50|
|Equity / Book Value||18.51M|
|Book Value Per Share||0.37|
In the last 12 months, operating cash flow was -$17.91 million and capital expenditures -$872,000, giving a free cash flow of -$18.78 million.
|Operating Cash Flow||-17.91M|
|Free Cash Flow||-18.78M|
|FCF Per Share||-$0.38|
Gross margin is 71.02%, with operating and profit margins of -396.05% and -354.35%.
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for Evogene is $3.62, which is 462.64% higher than the current price. The consensus rating is "Strong Buy".
|Price Target Difference||462.64%|
|Analyst Consensus||Strong Buy|
|Revenue Growth Forecast (5Y)||n/a|
|EPS Growth Forecast (5Y)||n/a|
The last stock split was on November 19, 2013. It was a reverse split with a ratio of 1:2.
|Last Split Date||Nov 19, 2013|
Evogene has an Altman Z-Score of -5.5 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.